Neuralink 2026 — VOICE, Blindsight, and Scale

Fetch status: summary-derived — neuralink.com/updates is JS-rendered and the dedicated trial write-ups (NeurApod) fetched cleanly for the VOICE/CONVOY/funding facts; Blindsight and patient-count details are triangulated across multiple consistent secondary summaries. Canonical Neuralink updates URL preserved.

Scale

• At least 21 successful implants by January 2026; at least 24 patients by May 2026 (up from ~12 by Sept 2025 in the prior KB snapshot).
• $650M raised in 2025, valuing Neuralink at ~$9 billion; plans for high-volume production and a shift to a fully automated surgical procedure.
• Realistic commercial-approval timelines still extend to ~2028–2030.

Three program tracks now running

1. VOICE — speech restoration (new)

• An early-feasibility study targeting the speech motor cortex for direct thought-to-speech.
• Two patients enrolled (as of early 2026); second participant Kenneth Shock, implanted at UT Southwestern (Dallas).
• Trial started October 3, 2025; estimated completion October 2028.
• FDA Breakthrough Device Designation for speech restoration (mid-2025). Musk publicly: "Neuralink is restoring speech to those who have lost the ability to speak."

2. CONVOY — robotic-arm control (PRIME extension)

• Tests whether PRIME participants can control assistive robotic arms with the same implant.
• Oct 2025: ALS participant Nick Wray used a robotic arm to drink from a cup, microwave food, open a refrigerator, and set records on stroke-patient dexterity tests (39 cylinders moved in 5 minutes).

3. Blindsight — vision restoration (new track)

• Stimulates the visual cortex to create visual perception in people who are completely blind, including those born blind with no functional eyes or optic nerves.
• FDA Breakthrough Device Designation September 2024; first human trial planned for 2026, in partnership with Cleveland Clinic Abu Dhabi (UAE). Demonstration video released April 1, 2026.

International expansion (PRIME family)

• CAN-PRIME (Canada, Nov 2024), GB-PRIME (UK, July 2025), UAE-PRIME (Cleveland Clinic Abu Dhabi).

Device

• "Telepathy" implant; the device's thread count is reported variously (the N1 carries 1,024 electrodes / 64 threads; some 2026 coverage cites 128 ultra-thin recording threads), with insertion time reduced to ~1.5 seconds. A second-generation device with a revised electrode design (addressing thread retraction) is in development for broader trials.

Significance

Neuralink in 2026 is no longer a single-application cursor demo. It is running three distinct clinical programs (motor/robotics, speech, vision), scaling patient numbers ~2× in months, and explicitly preparing manufacturing and automated surgery for volume. The competitive frame has shifted from "does intracortical BCI work" to "which application reaches approval first, and can surgery be industrialized."